These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18322300)

  • 21. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.
    Cataldo NA; Abbasi F; McLaughlin TL; Basina M; Fechner PY; Giudice LC; Reaven GM
    Hum Reprod; 2006 Jan; 21(1):109-20. PubMed ID: 16155076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
    Trolle B; Lauszus FF; Frystyk J; Flyvbjerg A
    Fertil Steril; 2010 Nov; 94(6):2234-8. PubMed ID: 20189560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V; Nagamani M
    J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
    Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
    Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
    Orbetsova M; Kamenov Z; Kolarov G; Zakharieva S; Khristov V; Atanasova I; Shigarminova R; Milcheva B; Genchev G
    Akush Ginekol (Sofiia); 2006; 45(7):16-28. PubMed ID: 17489164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.
    Tan BK; Adya R; Chen J; Farhatullah S; Heutling D; Mitchell D; Lehnert H; Randeva HS
    Cardiovasc Res; 2009 Aug; 83(3):566-74. PubMed ID: 19414528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
    Legro RS; Zaino RJ; Demers LM; Kunselman AR; Gnatuk CL; Williams NI; Dodson WC
    Am J Obstet Gynecol; 2007 Apr; 196(4):402.e1-10; discussion 402.e10-1. PubMed ID: 17403436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome].
    Zhang CL; Gao HY; Zhao ZG; Jia P
    Zhonghua Fu Chan Ke Za Zhi; 2004 Mar; 39(3):173-5. PubMed ID: 15130377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raised serum, adipocyte, and adipose tissue retinol-binding protein 4 in overweight women with polycystic ovary syndrome: effects of gonadal and adrenal steroids.
    Tan BK; Chen J; Lehnert H; Kennedy R; Randeva HS
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2764-72. PubMed ID: 17456573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome].
    Vrbíková J; Hill M; Stárka L; Cibula D; Snajderová M; Sulcová J; Vondra K; Bendlová B
    Cas Lek Cesk; 2001 Nov; 140(22):688-94. PubMed ID: 11789058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
    Fruzzetti F; Perini D; Russo M; Bucci F; Gadducci A
    Gynecol Endocrinol; 2017 Jan; 33(1):39-42. PubMed ID: 27808588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
    Kebapcilar L; Taner CE; Kebapcilar AG; Alacacioglu A; Sari I
    Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations--introductory report.
    Marciniak A; Nawrocka-Rutkowska J; Brodowska A; Sienkiewicz R; Szydłowska I; Starczewski A
    Folia Histochem Cytobiol; 2009; 47(2):323-8. PubMed ID: 19995720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
    Nascimento AD; Silva Lara LA; Japur de Sá Rosa-e-Silva AC; Ferriani RA; Reis RM
    Gynecol Endocrinol; 2013 Mar; 29(3):246-9. PubMed ID: 23194004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome.
    Hamed HO
    J Obstet Gynaecol Res; 2013 Dec; 39(12):1596-603. PubMed ID: 23875783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin resistance directly contributes to androgenic potential within ovarian theca cells.
    Qu J; Wang Y; Wu X; Gao L; Hou L; Erkkola R
    Fertil Steril; 2009 May; 91(5 Suppl):1990-7. PubMed ID: 18672234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.